Tag Archive for: Appointment

Numab Therapeutics Appoints Dr. Rajesh Chopra as Chief Scientific Officer to Advance its Proprietary Multispecific Antibody Pipeline

/in

Appointment brings extensive experience spanning drug discovery, translational medicine, clinical development and scientific leadership HORGEN, Switzerland, October 1, 2026 – Numab Therapeutics (“Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology and oncology, today announced the appointment of Rajesh Chopra, M.D., PhD, as Chief Scientific Officer. Read more…

Read more

Hansa Biopharma Announces New Board Appointments

/in

Lund, Sweden, September 24, 2026. Hansa Biopharma AB (publ), “Hansa” (Nasdaq Stockholm: HNSA), announced today the election of Shannon Campbell and Gregory Perry to Hansa’s Board of Directors, effective September 22, 2026 until the end of the next Annual General Meeting. Read more…

Read more

Actithera significantly strengthens leadership team and Board as Company advances towards clinical development

/in

Steven Kelly appointed Chief Executive Officer to lead Actithera through clinical development and continued pipeline expansion Briggs Morrison appointed Chair of the Board, bringing extensive biotech leadership and oncology drug development expertise John Crowley appointed Independent Director, adding proven strategic, financial and capital markets leadership Oslo, Norway and Cambridge, Massachusetts — 10 September 2026 — […]

Read more

Simris Group Appoints Biotechnology Expert Dr. Tiffany J. Vora as Strategic Advisor

/in

Hammenhög, Sweden, July 28, 2026 — Simris Group AB (SIMRIS B) today announced the appointment of Dr. Tiffany J. Vora as a Strategic Advisor. Dr. Vora is a biotechnology scientist, entrepreneur, educator, and advisor with experience across molecular biology, genomics, biotechnology innovation, and drug discovery. Through her work with technology companies, startups, scientific organizations, and the broader innovation […]

Read more

ReBio Pharma appoints leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer

/in

· Brings nearly three decades of clinical, translational and biotechnology experience, strengthening ReBio’s leadership team as it prepares to advance RBP-01 into the clinic · RBP-01 targets primary uveal melanoma, the most common primary eye cancer in adults and an indication with no approved therapies Turku, Finland and Geneva, Switzerland, 22 July2026 – ReBioPharma (“ReBio” […]

Read more
© Optimum Strategic Communications.